WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406643
Description: ISA-2011B is a PIP5Kα (Phosphatidylinositol-4-phosphate 5-kinase-α) inhibitor. The overexpression of PIP5K1α is associated with poor prognosis in prostate cancer and correlates with an elevated level of the androgen receptor. ISA-2011B significantly inhibits growth of tumor cells in xenograft mice, which is mediated by targeting PIP5K1α-associated PI3K/AKT and the downstream survival, proliferation, and invasion pathways. PIP5K1α has high potential as a drug target, and compound ISA-2011B is interesting for further development of targeted cancer therapy.
MedKoo Cat#: 406643
Chemical Formula: C22H18ClN3O4
Exact Mass: 423.09858
Molecular Weight: 423.85
Elemental Analysis: C, 62.34; H, 4.28; Cl, 8.36; N, 9.91; O, 15.10
Synonym: ISA2011B; ISA 2011B; ISA-2011B; ISA2011-B; ISA 2011-B; ISA-2011-B.
IUPAC/Chemical Name: (5S,10aS)-5-(5-chloro-1H-indol-3-yl)-9-methyl-8,9,10a,11-tetrahydro-5H-[1,3]dioxolo[4,5-g]pyrazino[1,2-b]isoquinoline-7,10-dione
InChi Key: FSEZESVJDPKRDS-UWJYYQICSA-N
InChi Code: InChI=1S/C22H18ClN3O4/c1-25-9-20(27)26-17(22(25)28)4-11-5-18-19(30-10-29-18)7-13(11)21(26)15-8-24-16-3-2-12(23)6-14(15)16/h2-3,5-8,17,21,24H,4,9-10H2,1H3/t17-,21-/m0/s1
SMILES Code: O=C(N1[C@H](C2=CNC3=C2C=C(Cl)C=C3)C4=C(C=C5C(OCO5)=C4)C[C@]16[H])CN(C)C6=O
1: Drake JM, Huang J. PIP5K1α inhibition as a therapeutic strategy for prostate cancer. Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):12578-9. doi: 10.1073/pnas.1413363111. Epub 2014 Aug 12. PubMed PMID: 25118275; PubMed Central PMCID: PMC4156720.
2: Semenas J, Hedblom A, Miftakhova RR, Sarwar M, Larsson R, Shcherbina L, Johansson ME, HÃ¤rkÃ¶nen P, Sterner O, Persson JL. The role of PI3K/AKT-related PIP5K1α and the discovery of its selective inhibitor for treatment of advanced prostate cancer. Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):E3689-98. doi: 10.1073/pnas.1405801111. Epub 2014 Jul 28. PubMed PMID: 25071204; PubMed Central PMCID: PMC4156761.